NEONC Secures $50M Global Deal to Advance Brain Cancer Therapies – NTHI x Quasar – NewsOut
For biotech investors and global healthcare leaders: NEONC Technologies (OTC: NTHI) has secured a $50 million strategic partnership with Quasar Investment, including a $35M equity investment at a significant premium and $15M in support for clinical trials and MENA-region expansion.
In this NewsOut report, Ana Berry breaks down how NEONC is launching Neuromina and Neurocure in Abu Dhabi to accelerate FDA Fast Tracked brain cancer treatments—NEO100 and NEO212. This milestone signals serious global momentum and growing investor upside in oncology innovation.
💰 $50M partnership with Quasar Investment
🧠 Advancing brain cancer drugs NEO100 & NEO212
🌍 Global expansion into UAE and MENA
📈 $25/share equity buy-in — above market
🚀 FDA Fast Track + Phase 2B trials
🏷️ Tags:
#NEONC
#NTHI
#BrainCancerTreatment
#NEO100
#NEO212
#QuasarInvestment
#BiotechInvesting
#FDAFastTrack
#MENAExpansion
#UAEBiotech
#OncologyInnovation
#ClinicalTrials
#Neurocure
#Neuromina
#NewsOut
#AnaBerry
#CancerResearch
